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Abstract FGFRL1 (fibroblast growth factor receptor like
1) is the most recently discovered member of the FGFR
family. It contains three extracellular Ig-like domains
similar to the classical FGFRs, but it lacks the protein
tyrosine kinase domain and instead contains a short intra-
cellular tail with a peculiar histidine-rich motif. The gene
for FGFRL1 is found in all metazoans from sea anemone to
mammals. FGFRL1 binds to FGF ligands and heparin with
high affinity. It exerts a negative effect on cell prolifera-
tion, but a positive effect on cell differentiation. Mice with
a targeted deletion of the Fgfrl1 gene die perinatally due to
alterations in their diaphragm. These mice also show
bilateral kidney agenesis, suggesting an essential role for
Fgfrl1 in kidney development. A human patient with a
frameshift mutation exhibits craniosynostosis, arguing for
an additional role of FGFRL1 during bone formation.
FGFRL1 contributes to the complexity of the FGF
signaling system.
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Introduction and lines of discovery
The fibroblast growth factors (FGFs) regulate a diverse
variety of cellular functions such as proliferation, differ-
entiation, migration, and apoptosis. FGF signaling is
therefore involved in most biological processes, including
embryonic development, organogenesis, angiogenesis,
wound healing, and tumor formation. Humans and mice
possess 18 different FGF ligands (FGF 1–10, FGF 15–23,
FGF 19 is the human orthologue of mouse FGF15) and four
FGF homologous factors (FGF 11–14) with unrelated
functions [1, 2]. The FGFs are monomeric proteins that
bind with high affinity to heparan sulfate proteoglycans,
whereby their activity is dramatically increased. Together
with the heparan sulfate, the FGFs bind to four different
FGF receptors (FGFRs) that belong to the receptor tyrosine
kinase family [3]. After ligand binding, the FGFRs
dimerize and trans-autophosphorylate specific tyrosine
residues in the cytoplasmic domain of the receptors. The
signal is then transduced to the interior of the cell by
various pathways including Ras/MAP kinase, phospholi-
pase Cc, PI3-kinase, and STAT. The FGFRs possess three
extracellular immunoglobulin(Ig)-like loops, a single
transmembrane domain, and an intracellular tyrosine
kinase domain [4]. The first Ig-like loop is separated from
the second by a stretch of negatively charged residues that
are often referred to as the ‘‘acidic box.’’ Mutations in
FGFRs can cause a number of skeletal disorders such as
craniosynostosis syndromes and chondrodysplasias [5].
Somatic mutations in the FGFRs may lead to unrestricted
growth and cancer as observed in bladder carcinomas [6]
and chronic myeloproliferative diseases [7].
FGFRL1 is the fifth member of the FGFR family [8].
It also contains three extracellular Ig-like domains and a
single transmembrane helix (Fig. 1). However, it does not
B. Trueb (&)
Department of Clinical Research, University of Bern,
Murtenstrasse 35, 3010 Bern, Switzerland
e-mail: beat.trueb@dkf.unibe.ch
Cell. Mol. Life Sci. (2011) 68:951–964
DOI 10.1007/s00018-010-0576-3 Cellular and Molecular Life Sciences
possess an intracellular protein tyrosine kinase domain but
instead harbors a C-terminal domain of only 100 residues
that cannot signal by transautophosphorylation. The
extracellular domain shares 32–35% sequence identity
(39–42% sequence similarity if conservative replacements
are included) with the extracellular domain of the con-
ventional FGFRs. In contrast, the intracellular domain does
not show significant similarity with any of the FGFRs or
with any other protein.
The novel receptor was described for the first time in the
year 2000 and termed FGFRL1 to emphasize its similarity
with the members of the FGFR family [8]. At that time,
sequences for human FGFRL1 were found in a cartilage-
specific cDNA library that had been prepared in order to
identify novel regulatory proteins that might play a role in
chondrocyte proliferation and differentiation. Shortly
thereafter, two other research groups described the same
protein and termed it FGFR5 [9, 10]. Kim et al. [9] used the
polymerase chain reaction with degenerate primers to
amplify cDNAs related to FGFRs. They provided evidence
that FGFR5/FGFRL1 was specifically expressed in the
human pancreas. Sleeman et al. [10] identified clones for
FGFR5/FGFRL1 in a cDNA library prepared from murine
peripheral lymph node. When these clones were hybridized
to a Northern blot containing RNA from nine different
tissues, expression of FGFR5/FGFRL1 was observed not
only in lymph nodes but also in kidney, liver, skeletal
muscle, heart, and lung. Since no RNA from cartilage and
bone had been included, other researchers repeated the
Northern blotting experiment with additional tissues [11,
12]. These studies confirmed that FGFRL1 was expressed
at relatively high levels in the cartilage of the sternum and
the primordia of the vertebrae; at moderate levels in heart,
tongue, aorta, lung, kidney, liver, and tendon; and at basal
levels in virtually all other tissues. The expression levels
increased steadily during mouse embryonic development
and became prominent after embryonic day E16 [12, 13].
In general, the expression appeared to be higher in mouse
tissues than in chicken or human tissues. By in situ
hybridization, the FGFRL1 mRNA was detected in all
cartilaginous structures such as the nasal cartilage, the
trachea, the ribs, and the primordia of the vertebrae and in
some muscles such as the muscles of the tongue and the
diaphragm [12]. However, compared to the expression of
the classical receptors, expression of FGFRL1 was always
relatively weak.
In addition to these studies with human and murine
tissues, the FGFRL1 mRNA was also cloned and
sequenced from rat [11], chicken [11], frog [14, 15], and
fish [16]. Zebrafish (Danio rerio) and pufferfish (Takifugu
rubripes) even possess two genes for FGFRL1, fgfrl1a and
fgfrl1b, because bony fish have undergone whole genome
duplication. The two genes exhibit slightly different
expression patterns, a fact that has fostered speculations
about subfunctionalization as the driving force to maintain
the two genes after duplication [16]. Xenopus laevis, a
species that is pseudo-tetraploid, also has two genes for
FGFRL1, while Xenopus tropicalis (Silurana) has only one
gene since this species is diploid [14, 15]. A protein with
60% sequence identity to human FGFRL1 was further
cloned from the cephalochordate Branchiostoma floridae
(lancelet) [15]. Since at that time no similar gene was
found in the urochordate Ciona intestinalis, the insect
Drosophila melanogaster, or the nematode Caenorhabditis
elegans, it was speculated that the FGFRL1 gene might
have evolved just before branching of the vertebrate line-
age from the other chordates. A few years later, however,
the gene for FGFRL1 was also cloned from the echinoderm
Strongylocentrotus purpuratus (sea urchin) [17]. Moreover,
Bertrand et al. [18] searched for putative orthologues of
FGFRL1 in the completely sequenced genomes of several
metazoans, and they identified FGFRL1 in the cnidarian
Nematostella vectensis (starlet sea anemone) as well as in
many other bilaterian species. They concluded that the
FGFRL1 gene is present in all metazoans and that it
might have evolved together with the other players of the
FGF signaling pathway. In flies (e.g., D. melanogaster),
nematodes (e.g., C. elegans), and urochordates (e.g.,
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Fig. 1 Schematic drawing of an FGFRL1 monomer. The signal
peptide, the three Ig-like domains, the linker (‘‘acidic box’’), the
transmembrane helix, and the intracellular domain are shown. The
disulfide bridges C–C, the signal peptidase cleavage site G–A, the site
of shedding S–S, the tandem tyrosine-based motif Y–Y, and the
Zn-binding region are indicated. Short arrows on the left side give the
relative positions of introns in the FGFRL1 gene. Note that FGFRL1
is a dimer under physiological conditions
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C. intestinalis), the FGFRL1 sequences might simply have
escaped our attention because these animals have evolved
at a much higher rate. The latter observation is illustrated
by the increased level of divergence of protein sequences
from flies, nematodes, and sea squirts when compared
to the corresponding sequences from cnidaria, annelida,
echinoderma, and vertebrates [19]. A phylogenetic tree
with the FGFRL1 sequences from ten different species is
shown in Fig. 2. This tree is in good agreement with our
current understanding of metazoan evolution.
Domain structure
FGFRL1 is a typical type I transmembrane protein with a
single membrane-spanning helix [8–10]. The extracellular
domain comprises a signal peptide, three Ig-like domains
termed D1, D2, and D3, and a linker region separating
domains D1 and D2 (see Fig. 1). Each of the three
Ig-domains is stabilized by a single disulfide bond. Fol-
lowing insertion into the endoplasmic reticulum, the signal
peptide is cleaved off. The site of cleavage in human
FGFRL1 occurs between Gly-17 and Ala-18 as recently
demonstrated by mass spectrometric analysis of the iso-
lated extracellular domain from human FGFRL1 [20]. The
signal peptide is therefore seven residues shorter than
predicted in the Swiss-Prot/UniProt database. At the
beginning of domain D2 there is a very basic region that is
probably responsible for the interaction of FGFRL1 with
heparin [11]. Ten positively charged residues are found at
this region of the human protein before the next negatively
charged residue follows. The FGF ligands are thought to
bind into the groove formed between D2 and D3, as is the
case with the classical FGFRs [1], but so far there is no
experimental evidence for this assumption. Also in analogy
with the conventional FGFRs one may predict that the first
Ig domain might have a regulatory or modulating function
in that it can fold back onto domain D2 and thereby occupy
or sterically hinder the interaction with heparin and/or FGF
ligands. The linker between domain D1 and D2 might
provide the necessary flexibility for bending. This linker is
the least conserved part of the entire extracellular domain
in a multiple sequence alignment of FGFRL1 from ten
different species (Fig. 3). Thus, the linker will barely have
a sequence specific function, but it might rather separate
the two domains and provide some flexibility. The best
conserved region in the multiple sequence alignment of
Fig. 3 is domain D3. Whether this conservation is a con-
sequence of FGF ligand binding is not known. The human
FGFRL1 sequence contains four glycosylation sites for the
attachment of asparagine-linked carbohydrates that are
conserved in all species except the starlet sea anemone.
Three of these sites are occupied by carbohydrates as
indirectly demonstrated by mass spectrometric analysis
[20]. These glycosylation sites are found at slightly shifted
positions also in the sea anemone sequence [18], while the
fourth site of the human sequence does not have a coun-
terpart in the sea anemone. The attachment of three to four
carbohydrate chains is consistent with the observed dif-
ference in molecular mass (10 kDa) when FGFRL1
synthesized by HEK293 cells in the presence of the gly-
cosylation inhibitor tunicamycin is compared to that
synthesized in the absence of the inhibitor [21].
The intracellular domain of FGFRL1 is only 100 amino
acids in length and does not contain any protein tyrosine
kinase domain. In a multiple alignment of ten vertebrate
sequences, this is the least conserved domain (Fig. 4).
The only convincing conservation is found at the very
C-terminal end where a peculiar histidine-rich sequence is
present. In the human sequence, ten histidine residues
alternate with other residues, often threonine (479-HTHTH
THSHTHSHVEGKVHQHIHYQC-504). Recently, it has
been noted that this histidine-rich sequence can interact
with zinc and nickel ions [17]. By atomic absorption, the
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Fig. 2 Phylogenetic tree of FGFRL1 from ten different species. An
unrooted tree was built by the neighbor-joining methods. Bootstrap
values from 1,000 random replicates are indicated at the nodes (given
in %). The length of the branches inversely correlates with the degree
of similarity. Note that only the extracellular domain without signal
peptide and transmembrane domain has been used for the phyloge-
netic analysis
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Fig. 3 Alignment of the extracellular domain of FGFRL1 from ten
different species. The signal peptidase cleavage site of human
FGFRL1 is indicated by an arrow. The three Ig-like domains are
shown by brackets. Glycosylation sites NXT in the human sequence
are indicated by asterisks. The accession numbers are as follows:
human AJ277437, mouse AJ293947, chicken AJ535114, frog
(Silurana tropicalis) AJ616852, fish A (T. rubripes A) BN000669,
fish B (T. rubripes B) BN000670, lancelet (B. floridae) AJ888866, sea
urchin (S. purpuratus) FN252817, shellfish (Lottia gigantea)
4236761:246, worm (Capitella capitata) 170033, sea anemone
(N. vectensis) 204525
Fig. 4 Alignment of the FGFRL1 sequences for the transmembrane
segment and the intracellular domain from eight different species.
The transmembrane helix is marked by brackets. The tandem
tyrosine-based motif is underlined, as is the histidine-rich sequence.
Accession numbers are as given in the legend to Fig. 3. The
sequences from worm and sea anemone have not been included since
these sequences are much longer and did not align properly. Note that
the mouse sequence appears to have suffered a frameshift mutation at
residue 475 during evolution [10, 11, 13]
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human sequence was demonstrated to bind three zinc
atoms. The intracellular domain can therefore be purified by
chromatography on a nickel affinity column after synthesis
in a bacterial expression system, a procedure that is usually
employed to purify recombinant proteins with an artificial
histidine tag. The histidine-rich sequence is preceded by the
tandem tyrosine-based motif PKLYPKLYTDI [10, 22].
This sequence resembles the tyrosine-based motifs
YXXUYXXU (where U is a bulky, hydrophobic amino
acid) that are well-known mediators of endocytosis and
transmembrane protein trafficking. In fact, truncation
experiments and in vitro mutagenesis demonstrated that
both the histidine-rich sequence and the tandem tyrosine-
based motif act as signals for trafficking of FGFRL1 from
the plasma membrane to endosomes and lysosomes [22].
When they were deleted or mutated, FGFRL1 was not
efficiently internalized and stayed at the plasma membrane
for a prolonged period of time.
A peculiar observation was made with the C terminus of
FGFRL1 from rodents. Compared to the human sequence,
the mouse and the rat C terminus must have suffered a
mutation during evolution, which led to the replacement of
part of the histidine-rich sequence by 54 unrelated residues
(see Fig. 4) [10, 11, 13]. Nevertheless, the unrelated
sequence must be able to compensate in some way for this
mutation since the mouse Fgfrl1 protein shows the normal
subcellular distribution. In particular, it does not stay at the
plasma membrane for a prolonged period of time as the
truncated protein described above [22].
Recently it has also been observed that FGFRL1 can be
shed from the plasma membrane [20]. Shedding was first
noted in cultures of myoblasts that were allowed to dif-
ferentiate into myotubes. In such cultures, virtually no
FGFRL1 was detected at the cell membrane but relatively
large amounts of a soluble form of FGFRL1 accumulated
in the cell culture media. The shed protein was also found
in the conditioned media of HEK293 cells that overex-
pressed FGFRL1. The exact cleavage site could be
localized by mass spectrometry to the center of a group of
four serine residues in the proximity of the transmembrane
domain, but so far the identity of the protease responsible
for shedding has not yet been elucidated [20]. Experiments
with proteinase inhibitors suggested that the enzyme was
not related to furin, b-secretase, or to a matrix metallo-
proteinase such as ADAM9.
When the overall structure of FGFRL1 was compared to
all proteins that are encoded by the human genome, 42
structurally related proteins with a signal peptide, three
Ig-like domains, and a single transmembrane helix were
identified [23]. These proteins fall into seven different
families, namely FGFRs, Fc receptor-like proteins, IL-1
receptor-like proteins, KIRs, nectin-like proteins, sialic
acid binding lectins (SIGLECs), and signal regulatory
proteins (SIRPs). It remains to be determined whether the
structural similarity found between FGFRL1 and all these
proteins will also extend to functional similarities.
Gene structure
The human FGFRL1 gene is found on the short arm of
chromosome 4 in band 4p16.3 [8], the mouse Fgfrl1 gene
on chromosome 5 in band E3-F [13]. Both genes comprise
seven exons. The first exon contains only the 50 noncoding
sequences and was numbered 0 in one publication [24].
The other exons, usually numbered 1–6, code for a separate
domain each, exon 1 for the signal peptide, exon 2 for
Ig domain D1, exon 3 for the linker (acidic box), exon 4 for
Ig domain D2, exon 5 for Ig domain D3 and exon 6 for the
transmembrane domain and the intracellular portion. All
these exons are flanked by introns of splice phase 1 where
the codons for the amino acids are interrupted after the first
nucleotide. The exon/intron structure is therefore much
simpler than that of the classical FGFRs, which possess up
to 19 exons. In these receptors, nine exons are needed to
code for the protein tyrosine kinase domain that is missing
in FGFRL1. Furthermore, FGFR1, FGFR2, and FGFR3 can
be alternatively spliced in the IIIB/IIIC region, a process
that requires three separate exons to code for domain D3
[1–3]. Thus, the only additional difference between the
exon/intron structure of the FGFRL1 gene and those of the
classical receptors concerns domain D2, which is encoded
by a single exon in FGFRL1 and by two exons in the
classical receptors. However, some deviation from the
prototype of the FGFRL1 gene structure is found in several
animals including lancelet and pufferfish where the D2
domain is also encoded by two exons [15, 16, 18]. Since
the splice phase of the inserted intron is of a different type
(splice phase 0, which does not interrupt the codon for the
amino acid), it is likely that this intron was inserted into the
FGFRL1 gene later during evolution.
Alternative splicing has also been observed with the
FGFRL1 gene. Sleeman et al. [10] described the existence
of two additional mRNA species that were lacking the
sequences for either the first Ig domain or the first
Ig domain plus the acidic box. The relevance of this
alternative splicing event is not known and no tissue-spe-
cific expression has yet been published.
Binding of FGF ligands
There is ample evidence that FGFRL1 does in fact interact
with FGF ligands. The first speculations came from mod-
eling studies in which the polypeptide chain of FGFRL1
was superimposed on the solved three-dimensional
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structure of FGFR1 [10]. This comparison demonstrated
that many of the residues that are involved in the interac-
tion with FGF ligands are well conserved in FGFRL1. As
previously shown, the FGFRs interact with the ligands
primarily via their domains D2 and D3 and the intercon-
necting linker D2–D3 [25, 26]. The contacts between the
FGFs and the D2 domain as well as the D2–D3 linker are
thought to be involved in general binding of the ligands,
while the contacts with the D3 domain appear to control the
ligand specificity of the receptor. Figure 5 shows an
alignment of the extracellular domains from human FGFR1
and FGFR2, whose structures have been solved [25, 26],
with that from human FGFRL1. In the FGF2/FGFR2
complex, residues Leu-166, Ala-168, and Pro-170 of D2
make hydrophobic contacts with the ligand. In the aligned
FGFRL1 sequence, these residues are conserved as
Val-159, Ala-161, and Pro-163. From the D2–D3 linker,
Arg-251 forms an important hydrogen bond with the
ligand. This residue is conserved as Arg-241 in FGFRL1.
In the D3 domain of FGFR2, several hydrogen bonds are
formed between residues Asp-283, Gln-285, Val-317, Asn-
318, and Asp-321 and several sites of the FGF ligand. In
FGFRL1, two of these residues are conserved as Asp-273
and Val-311. Since Gln-285, Asn-318, and Asp-321 are not
conserved and since these bonds control mainly the ligand
specificity, one may speculate that FGFRL1 might have
other specificities than FGFR2 and FGFR1.
A direct interaction was experimentally demonstrated
with FGF2 and recombinant mouse FGFRL1 (FGFR5) that
carried an Fc-tag [10]. When the receptor was incubated
with FGF2 and then precipitated with protein G-Sepharose,
the precipitates contained nearly stoichiometric amounts of
FGF2. This interaction was specific since FGF7 or EGF
could not be precipitated in control experiments [10]. In a
subsequent publication, radiolabeled FGF2 and recombi-
nant chicken FGFRL1 with a His-tag were utilized for a
similar experiment [11]. The radiolabeled growth factor
bound to FGFRL1 and was specifically co-precipitated
with nickel agarose beads. A dissociation constant Kd of
6 nM was determined for the FGF2/FGFRL1 complex.
More recently, a dot blot assay was utilized to test all
commercially available FGFs for their ability to bind to
recombinant human FGFRL1 that had been produced in
HEK293 cells with an myc tag [20]. The growth factors
were spotted onto a nitrocellulose membrane and incubated
with the soluble FGFRL1. After washing, bound receptor
was detected with anti-myc antibodies. Strong binding was
observed with FGF3, FGF4, FGF8, FGF10, and FGF22,
whereas virtually no binding was obtained with FGF1,
FGF6, FGF7, FGF9, FGF12, FGF16, FGF19, FGF20, and
FGF21. FGF2, FGF5, FGF17, and FGF23 showed inter-
mediate binding. Some of these results were verified in a
cell-based ligand binding assay. FGF1, FGF2, FGF3, and
FGF12 were fluorescently labeled with DyLight 547.
HEK293 cells that stably expressed FGFRL1 on their cell
surface were incubated with the fluorescent ligands. Only
FGF2 and FGF3 bound to the cell surface, while FGF1 and
FGF12 did not bind [20, 22]. For FGF3, the dissociation
constant Kd was directly determined by surface plasmon
resonance. The ligand was coupled to the surface of a
Biacore sensor chip and increasing concentrations of sol-
uble FGFGRL1 were injected over the chip [22]. Typical
Fig. 5 Alignment of the FGF ligand binding sites from human
FGFR1 (NP 075598) and human FGFR2 (NP 000132) with the
extracellular domain of human FGFRL1 (AJ277437). Identical
residues are boxed. The three Ig-like domains are shown by brackets.
Residues that are involved in ligand binding in the FGF1/FGFR1 and
FGF2/FGFR2 complex are encircled
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interaction curves with relatively quick association and
slow dissociation constants were observed, from which a
Kd of 4 nM was determined. This affinity is at least one
order of magnitude higher than the affinities published for
most FGFs and their cognate receptors. Such Kd values
have been described so far only for mutant receptors as
they are found in Pfeiffer, Apert, and Muenke craniosyn-
ostosis syndromes [27]. Many cases of these syndromes are
caused by gain-of-function mutations occurring in the
D2–D3 linker, either at Ser-252 (S252W) or Pro-253
(P253R). The mutant receptors exhibit affinities that are
roughly one order of magnitude higher than those of the
wild-type receptors (e.g., 4 9 10-9 for FGF2/FGFR2c
P253R) and therefore in the region of the Kd determined for
FGFRL1 [27]. In this context, it should also be noted that
FGFRL1 has an arginine residue at position 243 that
exactly matches the gain-of-function mutation P253R
detected in Apert syndrome (Fig. 5). This substitution
could therefore be responsible for the unexpectedly high
affinity of FGF3 for FGFRL1.
Together, the co-precipitation experiments, the ligand
dot blot assays, the cell-based ligand binding studies, and
the plasmon resonance measurements clearly demonstrate
that FGFRL1 is a genuine FGF receptor with high affinity
for some FGF ligands.
Heparin binding
The classical FGFRs bind to heparin and heparan sulfate,
and this heparin binding activity is believed to be important
for receptor dimerization and subsequent signaling [1, 3,
28]. Already in the year 1993, the major heparin binding
site of FGFR1 was traced to a basic peptide of 18 residues
occurring at the beginning of Ig-like domain D2 [29].
Several years later, the dissociation constants Kd were
determined for the heparin/FGFR1 (63 nM) and the hepa-
rin/FGFR2 complexes (13 nM) [30].
Similar to the classical receptors, FGFRL1 also interacts
with heparin. This interaction has enabled the authors to
purify recombinant protein from conditioned media of
several cell lines by affinity chromatography [11, 21]). The
heparin affinity of FGFRL1 appears to be substantially
higher than those of the classical receptors since an ionic
strength corresponding to 600–700 mM NaCl is required to
displace FGFRL1 from a heparin column [21] as compared
to 330 mM NaCl (FGFR1 [30]), 430 mM NaCl (FGFR2
[30]), 300–400 mM NaCl (FGFR4 [31]), and 200 mM
NaCl (FGFR3; Zhuang, personal communication) that are
required to displace the other receptors from heparin col-
umns. From the solved three-dimensional structure, it is
known that heparin binds into a positively charged canyon
formed by domain D2 and FGF [28]. A similar positively
charged groove can also be predicted by three-dimensional
modeling for the FGFRL1 polypeptide chain. The major
cluster of positively charged arginine and lysine residues
occurs at the beginning of domain D2. When selected
residues from this cluster were exchanged with uncharged
or negatively charged residues by in vitro mutagenesis, the
mutant protein interacted with heparin-Sepharose with
reduced affinity and required only 500 mM instead of
700 mM NaCl for displacement [22]. Preliminary mea-
surements with an optical biosensor produced a Kd of 9 nM
for the heparin/FGFRL1 complex (Zhuang and Trueb,
unpublished observation).
Potential ways of signaling
FGFRL1 cannot signal by transautophosphorylation as
there is no intracellular tyrosine kinase domain. FGFRL1
might therefore function as a simple decoy receptor that
binds FGF ligands and sequesters them away from the
conventional FGFRs [10, 11, 20]. Similar decoy receptors
have been described in the literature, in particular in the
immune system, where they modulate cellular responses to
cytokines. An example would be the IL-1 receptor 2
(IL-1 R2), which binds IL-1 but does not contain the
intracellular TIR (TOLL/IL-1 receptor) domain required
for signal transduction [32]. Thus, IL-1 R2 sequesters
ligands from the signaling receptor IL-1 R1 and reduces
IL-1-mediated inflammatory signals.
An alternative way to function would be that FGFRL1
dimerizes with a conventional FGFR and blocks in this
way transautophosphorylation since the dimeric complex
would have only one tyrosine kinase domain. This possi-
bility seems unlikely because FGFRL1 is known to form
constitutive homodimers even in the absence of FGF and
heparin [21]. Moreover, FRET analysis did not reveal any
evidence for the existence of heterodimers formed between
FGFRL1 and FGFR1–4 [21].
Another possibility would be that FGFRL1 accelerates
the internalization and degradation of the actively signaling
receptors. A prerequisite for this possibility would be that it
localizes to the same subcellular compartments as the
conventional receptors. When FGFRL1 is internalized and
sorted to the endosomes/lysosomes, for instance by its
histidine- and tyrosine-based motifs, it could drag along
some of the actively signaling receptors. This would be
facilitated when a single heparan sulfate chain interacted
with both FGFRL1 and the classical FGFRs. At present
such a mechanism is purely speculative, and no evidence
has been reported in favor of it.
A further possibility would include that FGFRL1
recruits other signaling molecules such as tyrosine phos-
phatases to the sites where the other signaling receptors are
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located. The peculiar intracellular domain with its tandem
tyrosine-based motif and its histidine-rich sequence could
be instrumental in the recruitment of such phosphatases. If
the phosphatases were brought into close contact to the
signaling receptors, they could remove phosphate groups
from the latter and attenuate signaling. A similar mecha-
nism has been described in the immune system. Several
transmembrane proteins including the Fc receptors [33],
the killer cell Ig-like receptors (KIRs) [34], and the
SIGLECs [35] harbor ITIM sequences (immunoreceptor
tyrosine-based inhibition motifs) in their C-terminal
intracellular domains. These ITIMs can become phos-
phorylated by src family kinases and subsequently bind
SH2-containing phosphatases such as SHP-1 and SHP-2
(phosphotyrosine phosphatase 1 and 2) [36, 37]. The
phosphatases can then dephosphorylate the cytoplasmic
domains of the adjacent receptors and in this way inhibit
activation of the cells. However, up to the present moment
no phosphorylation of the intracellular domain of FGFRL1
has been observed.
It is obvious that the above list of potential signaling
mechanisms is not exhaustive. Moreover, the proposed
ways of signaling are not mutually exclusive. For example,
it is well conceivable that the extracellular domain of
FGFRL1 acts as a decoy receptor while the intracellular
domain acts as a docking site for phosphatases.
Biological effects of FGFRL1
FGFRL1 exerts a variety of seemingly different effects on
cells in culture that are difficult to reconcile by a single
functional activity. On the one hand, FGFRL1 inhibits cell
proliferation and promotes cell differentiation. On the other
hand, it induces cell adhesion and appears to be involved in
cell–cell fusion.
The first effect was observed with MG63 osteosarcoma
cells that had been transfected with expression constructs
for FGFRL1 [11]. When compared to control cells treated
with anti-sense constructs, cells transfected with sense
constructs proliferated at a much slower rate. It was
therefore concluded that FGFRL1 exerted a negative effect
on cell proliferation. These experiments were later repeated
with an inducible system utilizing HEK293-TetOn cells
that express FGFRL1 from a construct, which is under the
control of the Tet transactivator [38]. In the absence of the
inducer doxycycline, these cells proliferated like normal
HEK293 cells. In the presence of the inducer, the cells
stopped growing and eventually started to die. Thus,
FGFRL1 has antiproliferative effects, at least when over-
expressed in cell culture.
A negative effect on cell proliferation and a positive
effect on cell differentiation are also consistent with the
relative expression of FGFRL1 during differentiation of
myoblasts in vitro [24]. When C2C12 cells or primary
myoblasts were grown in culture under proliferative con-
ditions (i.e., in the presence of FGF2 or relatively high
serum concentrations), the expression of FGFRL1 was
minimal. However, when the serum or the growth factors
had been removed and the cells were allowed to differen-
tiate into multinucleated, postmitotic myotubes, the
expression of FGFRL1 was sharply up-regulated. Thus,
FGFRL1 expression correlated directly with the differen-
tiation state of the cells.
In addition to the antiproliferative and proapoptotic
effects observed in cell culture, FGFRL1 also exerts a
profound effect on cell adhesion. The protein is usually
found at sites of cell–cell contact [21]. When coated on
plastic surfaces, the extracellular soluble domain of
FGFRL1 promoted adhesion of various mammalian cells
lines including HEK293, 3T3, and CHO. No similar effect
was observed with the extracellular, soluble domain of
FGFR1. It is likely that this adhesion-promoting activity of
FGFRL1 is mediated by heparan sulfate proteoglycans
expressed at the surface of the cultivated cells for it was
specifically blocked by the addition of soluble heparin or
by mutation of the heparin-binding site in the D2 loop of
the immobilized FGFRL1 [21].
Recently, it has also been observed that FGFRL1 has a
peculiar effect on cell–cell fusion [38]. The fusion of
mammalian cells into large syncytia is a well controlled
process that is restricted to a limited set of cells, including
gametes, macrophages, myoblasts, and trophoblasts [39,
40]. Steinberg et al. [38] demonstrated that the FGFRL1
receptor, when overexpressed, was capable of fusing CHO
cells into multinucleated syncytia comprising several
hundred nuclei. A particularly strong effect was observed
with FGFRL1DC (a construct that lacked the intracellular
domain but still retained the transmembrane domain), but
cell fusion could also be induced with the full-length pro-
tein. Truncation experiments further demonstrated that
Ig domain D3 and the transmembrane domain were both
necessary and sufficient for the fusion activity. The novel
receptor was even able to fuse heterologous cells, such as
HEK293 or HeLa cells, with untransfected CHO cells [38].
FGFRL1 is therefore the first mammalian protein that is
capable of inducing syncytium formation of heterologous
cells in vitro. It is possible that this activity is involved in
the differentiation process of myoblasts into multinucleated
myotubes.
Animal models
The first animal experiments with FGFRL1 were per-
formed by Cebria et al. [41] in the planarian Dugesia
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japonica. These flatworms possess two FGFRs, termed
DjFGFR1 and DjFGFR2 [42], and a single FGFRL1
termed nou-darake (Japanese for ‘‘brains everywhere’’).
Similar to vertebrate FGFRL1, the nou-darake protein has
three extracellular Ig-like domains (the membrane proxi-
mal domain D3 was not indicated in the original
publication), a transmembrane domain, and a relatively
short intracellular domain [41]. However, the intracellular
domain does not contain the histidine-rich sequence typical
of vertebrate FGFRL1. Nou-darake is specifically expres-
sed in the head region of the animals. Its function was
investigated by RNA interference with dsRNA that was
injected directly into the animals. Interestingly, depletion
of nou-darake mRNA resulted in the formation of ectopic
brain tissue throughout the body, therefore the name ‘‘brain
everywhere.’’ The ectopic brain formation could be sup-
pressed by the simultaneous injection of dsRNAs against
the two DjFGFRs, suggesting that nou-darake regulates
signaling by these FGFRs in a negative way. The authors
speculated that FGF ligands might act as brain-inducing
factors and that the diffusion radius of these factors is
restricted by nou-darake to the planarian head [41]. This
interpretation is consistent with a decoy function of nou-
darake.
Functional studies were also performed in zebrafish
embryos by Hall et al. [43]. These authors found evidence
for an essential role of FGFRL1 during craniofacial
skeletogenesis. Depletion of the zebrafish mRNAs for
Fgfrl1a and Fgfrl1b with morpholino constructs caused a
severe reduction in the formation of the cartilage elements
in the developing pharyngeal arches, especially in bran-
chial arches 3–5. The authors concluded that Fgfrl1 is
required for gill cartilage development. Moreover, they
provided evidence that Fgfrl1 might control the expression
of Gcm2 (glial cells missing 2), a transcription factor that
had previously been implicated in the formation of gill
cartilage [44, 45].
Another study was performed in Xenopus embryos [20].
From previous experiments it was known that overex-
pression of a truncated form of FGFR1, termed XFD,
disrupted the normal development of Xenopus embryos by
interfering with FGF signaling in a dominant-negative way
[46]. The resulting animals showed gastrulation defects
that affected trunk and tail and impaired notochord and
muscle development. In the more recent experiments,
injection of human or mouse FGFRL1 mRNA into Xeno-
pus blastomers led to the same posterior-ventral truncation
phenotype of the animals [20]. The dominant-negative
effect of the injected FGFRL1 mRNA could be reversed by
co-injection of mRNA for FGFR1. Thus, these experiments
clearly demonstrate that FGFRL1 interferes with FGF
signaling. Similar experiments with Xenopus embryos have
also been performed with the nou-darake mRNA [41]. In
this context, it is worth emphasizing that the negative
effects on FGF signaling were even observed when RNA
for the soluble, extracellular form of FGFRL1/nou-darake
was injected into the animals. It is therefore likely that
FGFRL1 functions as a simple decoy receptor in these
Xenopus experiments.
A severe phenotype was found in three different mouse
models, in which Fgfrl1 expression had been abolished by
targeted gene disruption. The first knock-out mouse was
described by Baertschi et al. [24]. These authors replaced
the first two exons (the noncoding exon 0 and the first
coding exon 1) by a neo cassette and studied the outcome
in homozygous and heterozygous offspring. Heterozygous
mice appeared to be normal as they did not display any
special phenotype until 2 years after birth. Homozygous
Fgfrl1-/- animals developed to term but died immediately
after birth due to respiratory distress. The respiratory
problems could be explained by a severe reduction of the
diaphragm muscle, which was not strong enough to inflate
the lungs after birth. The thickness of the diaphragm
muscle reached barely 60% of that of the control animals,
and certain areas of the diaphragm remained amuscular.
Other skeletal muscles such as the muscles of the leg did
not appear to be affected [24]. In addition to the diaphragm
phenotype, homozygous knock-out mice showed subtle
alterations in their skeleton, especially in their head [22].
They had a dome-shaped skull with high front that was
reminiscent of certain mouse models for human cranio-
synostosis syndromes.
The most striking phenotype of the Fgfrl1 knock-out
animals, however, was the virtual absence of the meta-
nephric kidneys [47]. During early embryonic
development, Fgfrl1 is normally expressed in the meta-
nephric mesenchyme and in the nascent renal vesicles.
At stage E10.5, the ureteric bud invades the metanephric
mesenchyme; subsequently, it branches several times and
induces the adjacent mesenchymal cells to undergo a
mesenchymal-to-epithelial transition [48]. In the mutant
animals, the ureteric bud showed severely reduced
branching and the nephrogenic mesenchyme did not
undergo the mesenchymal-to-epithelial transition. The
failure of the induction of nephrons could be explained by a
lack of expression of the nephrogenic markers Wnt4, Fgf8,
Pax8, and Lim1 in the mutant kidney rudiments [47]. Thus,
Fgfrl1 appears to be essential for the induction of the
metanephric mesenchyme. It is of interest to note that other
organs where branching morphogenesis plays a funda-
mental role, such as the lungs, did not appear to be affected
in the mutant animals.
It is conceivable that part of the bone phenotype
described above is secondary to the missing kidneys.
Bilateral renal agenesis is known to cause oligohydram-
nios, a deficiency of amniotic fluid sometimes also referred
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to as the Potter syndrome or the Potter sequence [49].
Fetuses with Potter syndrome show many signs of intra-
uterine compression, including facial dysmorphia with
large, low-set ears, redundant skin, limb-positioning
defects, arthrogryposis, and lung hypoplasia. Skull ossifi-
cation defects with large fontanels and sutures are a
frequent component of the disease. It is likely that the
missing kidneys will also affect the renin-angiotensin
system (RAS) of the growing fetus since renin is usually
produced in the afferent arterioles of the kidneys, even
during fetal life [50]. When renin is absent from the cir-
culation, angiotensinogen cannot be converted to
angiotensin, and the fetus will experience life-threatening
hypotension. Skull ossification defects are a common
consequence of the low blood pressure since nascent bones
require a high oxygen tension for normal growth [50]. It is
therefore likely that at least part of the skeletal abnormal-
ities of the Fgfrl1-deficient embryos can be explained by
the missing kidneys.
A second mouse model was developed by Anderson
et al. [51] and published as a patent application (US patent
20070292438). Although these authors did not provide any
detailed description of the final targeting vector or any
detailed analysis of the resulting phenotype, they clearly
stated that the homozygous Fgfrl1-/- mice died around
birth. Of note, their mice exhibited a fully penetrant kidney
phenotype with bilateral kidney agenesis as described by
Gerber et al. [47]. At embryonic stage E10.5 the ureteric
bud of the Fgfrl1-deficient mice invaded the metanephric
mesenchyme, but then failed to branch to form the char-
acteristic T-shaped structure. Expression of Pax2 and
Wnt11b was severely reduced in the metanephric mesen-
chyme. The authors proposed that Fgfrl1 is one of the key
regulators of early kidney development [51]. Since the
phenotypes of the mice created by Baertschi et al. [24] and
those created by Anderson et al. [51] are highly similar,
bilateral kidney agenesis must be considered a general
phenomenon of Fgfrl1 knock-out mice.
A third knock-out mouse has been created by Catela
et al. [52]. These authors did not remove the promoter
region but deleted the coding exons 2–6 of the Fgfrl1 gene.
Similar to the mice of Baertschi et al. [24] and Anderson
et al. [51], their heterozygous Fgfrl1?/- mice did not reveal
any abnormalities. The homozygous Fgfrl1-/- mice
showed the severe diaphragm defects described above and
died perinatally or even prenatally [52]. In addition, the
authors observed hypoplasia of most skeletal elements,
including shortened axial and appendicular bones and
malformed vertebrae. Furthermore, the embryos had con-
genital heart defects such as thickened ventricular valves
and septation anomalies. They suffered from a transient
fetal anemia that was claimed to be the cause for the rel-
atively high incidence of prenatal lethality. Finally, the
authors suggested that their knock-out mice might provide
a novel animal model to study the human Wolf-Hirschhorn
syndrome (see also below). However, Catela et al. [52] did
not mention any data about the missing kidneys. It is
therefore not clear at the moment whether some of the
observed alterations are actually secondary defects caused
by the potentially lacking kidneys.
FGFRL1 in human diseases
The first human mutation in FGFRL1 was identified by
Rieckmann et al. [22] in a craniosynostosis patient.
Screening of the genomic DNA from 55 patients with
various congenital skeletal malformations led to the iden-
tification of one patient with a frameshift mutation in the
intracellular domain of FGFRL1. This female patient pre-
sented with craniosynostosis, radio-ulnar synostosis, and
genital abnormalities and had previously been diagnosed
with Antley-Bixler syndrome. She was heterozygous for an
insertion of four nucleotides close to the C terminus of
FGFRL1. The insertion caused an elongation of the poly-
peptide chain from 504 amino acid residues to 551
residues. In addition, this patient harbored two mutations in
P450 oxidoreductase, an enzyme involved in the synthesis
of several steroid hormones. Cell culture experiments
showed that the mutant FGFRL1 protein stayed mainly at
the plasma membrane where it could interact with FGF
ligands, while the wild-type protein was preferentially
located in vesicular structures and in the Golgi complex.
The authors speculated that the mutation might lead to an
overactivity of the FGFRL1 receptor and contribute in this
way to the skeletal malformations of the patient [22].
In contrast to the three mouse models described above that
show FGFRL1 loss-of-function, this patient would there-
fore represent an example with FGFRL1 gain-of-function.
That FGFRL1 is indeed expressed in the growth plate of
long bones had previously been demonstrated by Lazarus
et al. [53]. These authors used microdissection followed by
qPCR and showed that FGFRL1 was expressed not only in
the perichondrium, but also in the growth plate of newborn
rats, preferentially in the resting zone.
There are a few reports in the literature that implicate
the FGFRL1 gene with the etiology of Wolf-Hirschhorn
syndrome. The primary cause of Wolf-Hirschhorn syn-
drome is a hemizygous deletion of variable size in the short
arm of chromosome 4 at 4p16 [54]. The major character-
istics of the disease are growth delay, craniofacial
dysgenesis, developmental delay, and epilepsy, but the
phenotype is highly variable. Mapping of the chromosomal
deletions from different patients identified two critical
regions termed WHSCR-1 and WHSCR-2. Both regions
comprise part of the WHSC1 gene, which was therefore
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made responsible for the craniofacial appearance of
patients with Wolf-Hirschhorn syndrome. Recently,
Engbers et al. [55] reported on a female patient with
characteristics of Wolf-Hirschhorn syndrome. This patient
had a terminal 4p16.3 deletion that included the FGFRL1
gene, but did not include the WHSC1 gene. The authors
therefore suggested that FGFRL1 might represent a
plausible candidate for the facial abnormalities of some
Wolf-Hirschhorn syndrome patients.
Catela et al. [52] resumed this idea and proposed
that their Fgfrl1 knock-out mouse might provide a novel
animal model for the dissection of the complex etiology of
Wolf-Hirschhorn syndrome. Their mice showed abnormal
craniofacial development, axial and appendicular skele-
tal anomalies, and congenital heart defects similar to
Wolf-Hirschhorn syndrome patients. However, there are
several pieces of evidence that would rather argue against
this animal model. In human patients, hemizygosity of one
or several genes in 4p16.3 is the generally accepted cause
for the craniofacial phenotype of Wolf-Hirschhorn syn-
drome [54], but none of the three Fgfrl1 knock-out mouse
models showed any abnormal phenotype if only one allele
of the Fgfrl1 gene was deleted (heterozygous mice) [24, 51,
52]. On the other hand, two of the Fgfrl1 knock-out mouse
models displayed bilateral kidney agenesis as the major
defect [47, 51], but kidney problems have not been asso-
ciated with Wolf-Hirschhorn syndrome [54]. It should also
be taken into consideration that the FGFRL1 locus is sit-
uated on 4p16.3 in close proximity to the FGFR3 locus.
It is therefore possible that the deletion of a locus control
region or of a remote enhancer element will influence the
expression of FGFR3 even when this gene is not directly
affected by the deletion.
Deletions in the chromosomal region 4p16 are also
found in some patients suffering from congenital dia-
phragmatic hernia [56], and there are several reports about
Wolf-Hirschhorn syndrome patients with congenital dia-
phragmatic hernia. The smallest deletion from the end of
the short arm of chromosome 4 associated with a dia-
phragmatic defect was determined as 2.4 Mb [57].
This deletion encompasses more than 40 different genes
including FGFRL1. Since Fgfrl1-deficient mice have a
hypoplastic diaphragm, the FGFRL1 gene was searched
for mutations in 54 patients with congenital diaphragmatic
hernia. Six established polymorphisms were found, but no
novel gene mutations [58]. The database of single nucle-
otide polymorphisms, dnSNP (http://www.ncbi.nlm.nih.
gov/snp), lists seven nonsynonymous SNPs that lead to
changes in the amino acid sequence (Table 1). Only three
of these SNPs occur with significant frequency in the
Caucasian population, namely P362Q, R424L, and P464L,
and all these SNPs are located within the last exon of the
FGFRL1 gene. One congenital diaphragmatic hernia
patient was found to be hemizygous for the minor allele of
two nonsynonymous SNPs (P362Q, P464L) [58]. It is
therefore conceivable that these polymorphisms predis-
pose the patient to diaphragmatic hernia. In this context, it
is interesting to note that the P362Q polymorphism occurs
at a site where the extracellular domain of FGFRL1 can
be cleaved and shed from the membrane. In fact, cell
culture experiments have demonstrated that the 362-Gln
variant is cleaved considerably better than the 362-P
variant [20]. It is therefore plausible that the 362-Gln
variant and eventually also the 464-L variant affect the
function of FGFRL1 in patients who are hemizygous for
this region.
Finally, alterations in FGFRL1 expression have been
observed in human tumors. A screen of 241 different
human tumors identified significant alterations in the rela-
tive expression in ovarian tumors [59]. Five ovarian tumors
were further analyzed by qPCR. While three tumors
showed a significant decrease in FGFRL1 expression, one
ovarian tumor exhibited a 25-fold increase in the relative
expression, suggesting major aberrations of FGFRL1
expression in ovarian cancer.
Concluding remarks
A new level of complexity was added to the FGF signaling
system when the klotho gene family was discovered [60,
61]. The klotho proteins convert the canonical FGFR1 into
a specific receptor for FGF23, FGF21, or FGF19, respec-
tively [61]. FGFRL1 now appears to add a further level of
complexity to the FGF signaling system. Although the
exact function of FGFRL1 is far from being understood, it
does represent a true player in the FGF signaling system
since it is able to interact with FGF ligands and with
heparin and since it evokes a cellular effect that ultimately
leads to reduced cell growth and accelerated cell differ-
entiation. While some of the properties of FGFRL1 are
relatively easy to explain, others appear rather difficult to
reconcile. For example, FGFRL1 binds to FGF2 as do all
the other FGFRs, but it does not bind to FGF1, which is
also recognized by all of the other FGFRs. The strongest
expression of Fgfrl1 is observed in cartilage but mice with
a targeted deletion of the Fgfrl1 gene do not show any
severe cartilage phenotype. These mice rather exhibit a
severe kidney phenotype with bilateral kidney agenesis,
although Fgfrl1 is not expressed at particularly high levels
in the developing kidneys. The expression levels of the
kidneys certainly do not exceed those of the developing
lungs, but the lungs appear to be normal in the mutant
mice.
It is possible that the FGFRL1 gene is one of the first
genes of the FGF/FGFR system that developed during
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evolution for it is already found in the first metazoans such
as the sea anemone [18]. This observation strongly
suggests that it might have evolved together with the other
members of the FGFR family. One should also consider the
possibility that FGFRL1 was even the first FGFR, which
subsequently gave rise to the evolution of the classical
FGFRs by acquiring a tyrosine kinase domain from an
unrelated receptor. The relative age of the FGFRL1 gene
may partly explain the fact that this receptor adopted
several seemingly different functions that are difficult to
reconcile to date. Besides its effects on cell growth, it also
promotes cell adhesion and cell–cell fusion, two properties
that so far have not been observed with any of the
canonical FGFRs.
Recently, FGFRL1 caught the attention of researchers
from different fields of biology because it repeatedly
emerged as one of the best candidates from several gen-
ome-wide screens. For example, FGFRL1 turned up in an
approach to identify novel human genes that show genomic
imprinting [62]. Imprinted genes are essential for the early
development of an embryo and dysregulation of imprinting
can lead to severe human diseases such as Prader-Willi
syndrome [63]. The authors of that study utilized a novel
algorithm to predict that FGFRL1 is expressed only from
the maternal allele, yet experimental verification of this
prediction is still missing [62]. A microarray-based search
for genes involved in self-renewal of embryonic stem
cells revealed that FGF signaling is one of the master
regulators of sustained self-renewal [64]. This study iden-
tified FGFRL1 as one of the top candidates that were
up-regulated in response to RNAi-mediated silencing of
the core transcription factors OCT4 and SOX2. Finally, a
study aiming at the identification of specific hypoxia-
regulated miRNAs detected mir-210 as the most prominent
miRNA induced under hypoxic conditions [65]. Interest-
ingly, one of the target genes of mir-210 that harbors
multiple mir-210 binding sites in its 30UTR turned out to be
FGFRL1. These authors further demonstrated that over-
expression of mir-210 reduced the growth of tumors when
cells from a head-and-neck tumor were injected into
immunodeficient mice. Interestingly, this inhibition could
be overcome by stable co-expression of FGFRL1 in the
injected cells [65]. Although the relevance of all these
observations is not yet fully clear, they nevertheless dem-
onstrate that the function of FGFRL1 goes well beyond that
of a mere decoy receptor for FGF ligands.
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